PKC-Theta Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for PKC-theta inhibition lack effectiveness and selectivity, particularly in distinguishing PKC-theta from other PKC isoforms and kinases, which hinders the development of potent and specific medical treatments for diseases associated with PKC-theta activity.
Innovation Solution
Development of novel compounds with specific structural formulas (e.g., Formula I, II, III) that act as PKC-theta inhibitors, offering a pharmaceutical composition for treating autoimmune disorders, inflammatory diseases, and cancers by modulating PKC-theta activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing PKC-theta inhibitors are used, then some inhibition effect is achieved, but selectivity over other PKC isoforms and kinases is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific structural features at particular positions in the molecular structure. Formula I compounds contain a pyrazolopyrimidine core with specific substituents at defined positions (R1-R10 variables), creating localized chemical properties that confer selective binding to PKC-theta over other PKC isoforms and kinases, thereby resolving the selectivity issue while maintaining inhibition effectiveness
2Reliability
If broader immunosuppressive mechanisms are used, then immune system suppression is achieved, but selectivity for PKC-theta inhibition is lost
Solution Approach 1:
The patent segments the PKC family into distinct isoforms with different structural and functional properties. By designing compounds that specifically target PKC-theta (Formula I, II, and III structures) rather than broadly suppressing all PKC isoforms, the invention achieves selective immunomodulation that maintains antiviral responses while providing PKC-theta specific inhibition for treating autoimmune and inflammatory conditions
Data Source
AI summary
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein. I